Virtu Financial LLC Cardiff Oncology, Inc. Transaction History

Virtu Financial LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 26, 2024	BUY	$0.96 - $1.55 $20,632 - $33,312	21,492 New	21,492 $32,000
Q4 2022 Feb 15, 2023	BUY	$1.22 - $1.66 $6,157 - $8,378	5,047 Added 14.71%	39,358 $55,000
Q3 2022 Nov 07, 2022	BUY	$1.54 - $3.21 $33,491 - $69,811	21,748 Added 173.11%	34,311 $53,000
Q2 2022 Aug 09, 2022	BUY	$1.17 - $2.61 $14,698 - $32,789	12,563 New	12,563 $28,000
Q3 2021 Nov 12, 2021	SELL	$5.01 - $7.58 $99,824 - $151,031	-19,925 Closed	0 $0
Q2 2021 Sep 17, 2021	SELL	$6.65 - $10.04 $88,644 - $133,833	-13,330 Reduced 40.08%	19,925 $133,000
Q1 2021 May 19, 2021	BUY	$9.1 - $19.57 $302,620 - $650,800	33,255 New	33,255 $308,000
Q4 2020 Feb 24, 2021	SELL	$12.02 - $24.71 $247,660 - $509,124	-20,604 Closed	0 $0
Q3 2020 Dec 11, 2020	BUY	$4.25 - $14.19 $87,567 - $292,370	20,604 New	20,604 $292,000

12.2M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $174M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.